Rocket One Inc. RKTO

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating

side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT);

and (iii) a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). We also have assets being

developed for (i) atopic dermatitis (also known as eczema) (BioLexa); (ii) a treatment for asthma and allergies using inhalational administration

Last close 0.55 2026-10-23
Market cap $13.6M 2026-06-30 share count
52-week range 0.48 - 2.45

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.90

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
R&D $5.9M$3.2M$3.7M$4.9M$7.4M$2.3M$2.0M$785.3K—
SG&A $6.4M$5.0M$4.2M$6.1M—————
Total operating expenses $12.4M$8.2M$8.0M$11.1M$14.1M$7.3M$7.7M$2.5M—
Operating income -$12.4M-$8.2M-$8.0M-$11.1M-$14.1M-$7.3M-$7.7M-$2.5M—
Net income -$12.5M-$8.2M-$8.1M-$11.4M-$14.3M-$7.2M-$7.7M-$2.5M—
EPS, basic -0.90-1.28-2.38-9.50-16.02————
EPS, diluted -0.90-1.28-2.38-9.50-16.02-0.58-0.84-0.50—
Shares, diluted (wtd. avg.) 13.8M6.4M3.4M1.2M893,226————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $6.2M$7.0M$9.3M$6.4M$8.5M$2.6M$1.9M$282.6K$1.2M
Short-term investments ———$209.3K—————
Total current assets $6.9M$7.6M$12.8M$7.7M$10.6M$4.8M$2.6M$501.6K$1.2M
Property, plant and equipment ——————$1.0K$2.3K$3.5K
Total assets $7.6M$7.7M$12.8M$7.7M$11.0M$5.2M$2.8M$503.9K$1.2M
Accounts payable $823.7K$412.1K$35.6K$695.0K$361.0K$129.5K$403.9K$142.3K$47.9K
Total current liabilities $1.5M$831.2K$678.7K$1.4M$867.8K$312.1K$440.1K$349.0K$49.5K
Total liabilities $1.5M$833.9K$705.0K$1.6M$1.1M$597.1K$440.1K$349.0K$49.5K
Retained earnings -$72.9M-$60.4M-$48.2M-$44.1M$983.5K-$19.4M-$12.2M-$4.5M-$2.0M
Total equity $6.2M$6.9M$9.5M$6.1M$9.9M$4.6M$2.4M$155.0K$1.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow -$9.8M-$7.0M-$8.4M-$9.3M-$12.1M-$6.1M-$4.9M-$2.1M—
Depreciation and amortisation —————$1.0K$1.2K$1.2K—
Stock-based compensation $1.2M$804.3K$216.4K$620.8K$1.3M$737.7K$2.5M$143.1K—
Investing cash flow -$300.0K——$1.2M-$165.4K-$1.8M-$895.0K——
Financing cash flow $9.3M$4.7M$11.3M$6.0M$18.2M$8.7M$7.5M$1.2M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-035625.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -15M -10M -5M 0 Net income, FY2018: -2.5M Net income, FY2019: -7.7M Net income, FY2020: -7.2M Net income, FY2021: -14.3M Net income, FY2022: -11.4M Net income, FY2023: -8.1M Net income, FY2024: -8.2M Net income, FY2025: -12.5M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — — — —
Gross profit — — — — — — — — —
Net income — -$2.5M -$7.7M -$7.2M -$14.3M -$11.4M -$8.1M -$8.2M -$12.5M

Recent filings and events

  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%